Ophthalmology
News, opinions and meeting coverage in ophthalmology.
β However, FDA approval isn't expected soon due to quirk in earlier results
Latest in Ophthalmology
Excess risk may be related to fluctuations in oxygenation that damage the retina
But the drug didn't appear to lower the risk of incident nonproliferative diabetic retinopathy
Optical assessments and machine-learning approaches allow for accurate diagnosis
But the drug didn't appear to lower the risk of incident nonproliferative diabetic retinopathy
Optical assessments and machine-learning approaches allow for accurate diagnosis
Ophthalmology Case Studies
Tropical parasitic disease is often asymptomatic, but beware of unexplained ocular symptoms
Case highlights risk-benefit considerations with concurrent bilateral intravitreal injections
Authors discuss how best to diagnose and manage him, given the absence of any symptoms
More in Ophthalmology
Post hoc analysis sparks discussion on their role in GA treatment and clinical trials
Closure of schools and cancelling of activities likely played a role
Tissue donation guided by different rules than organ donation, with less transparency, some say
Risks include vision-threatening infections, inflammatory issues, pigment migration
In the third year, 88% of patients could go 12 weeks or longer with 8-mg dose
Ophthalmologists say findings emphasize the importance of adhering to medication regimens
Delegates express concerns that PPE doesn't always cover women, who are more at risk of exposure
Peter K. Kaiser, MD, leads a discussion about the presentation given by Yasha S. Modi, MD, at AAO
Members also debate alternative ways states can safely license foreign med-school graduates
Ophthalmologists hope expanded use will lead to more evaluations in primary clinics
Valeda photobiomodulation system slowed disease progression and improved vision
Peter K. Kaiser, MD, leads a discussion from the AAO meeting
Retired physician Jay Berger, MD, reportedly suffered a mental health crisis
Provision in drug act would prohibit repackaging Avastin, add millions to anti-VEGF therapy cost
